January 30, 2019
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
Read More
January 30, 2019
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
Read More
January 30, 2019
Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma
Read More
January 30, 2019
SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma
Read More
January 30, 2019
Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma
Read More
January 30, 2019
Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects
Read More
January 30, 2019
Validation of an Index of Neutropenia (D-index) in Febrile Neutropenic Cancer Patients
Read More
January 30, 2019
Autologous Bone Marrow Mononuclear Cells in Liver Cirrhosis
Read More
January 30, 2019
PROPHESYS 1: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Virus (HCV)Treated With Pegasys (Peginterferon Alfa-2a)
Read More
January 30, 2019
Interferon α 2b Pharmacovigilance Study
Read More
January 30, 2019
POTENTE Study: A Study of Early Virological Response in Naive Patients With Chronic Hepatitis C, Genotype 2 or 3, Treated With PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Copegus (Ribavirin).
Read More
January 30, 2019
A Study of Sustained Virological Response in Relation to IL28-b Expression in Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1 on Combination Treatment With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)
Read More
Load More
X